Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | See Remarks | February 19, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date February 19, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2036-02-18 | Direct | 35,000 |
Reported balance
After 2026-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 20, 2026 16:16 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001193125-26-061396 · ownership.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 16:16 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 4,225 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001193125-25-306729 · ownership.xml · derivative · entry 2 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,775 Underlying: Common Stock · 4,225 shares Expires 2032-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 16:16 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 4,225 | $0.51 | $2,158.98 |
DisclosureSEC source: 0001193125-25-306729 · ownership.xml · nonDerivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,870 shares purchased through the Issuer's employee stock purchase plan. Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 16:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantPerformance Stock Option (right to buy) · Derivative | 8,550 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-25-080889 · ownership.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,110 Underlying: Common Stock · 8,550 shares Expires 2034-02-14 F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 8,550 shares of common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 16:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantPerformance Stock Option (right to buy) · Derivative | 4,560 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-25-037882 · ownership.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2034-02-14 F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 41,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000950170-25-024109 · ownership.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 41,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 16:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0000950170-24-137255 · ownership.xml · derivative · entry 2 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 15,000 shares Expires 2032-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 16:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 15,000 | $0.51 | $7,665.00 |
DisclosureSEC source: 0000950170-24-137255 · ownership.xml · nonDerivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,935 shares purchased through the Issuer's employee stock purchase plan. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 16:44 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-24-016469 · ownership.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2034-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2024. The 28,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 17:34 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-23-010202 · doc4.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2023. The 40,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-009739 · doc4.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-10 F1 · derivative.exercise_date: This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 19:04 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0000899243-21-016010 · doc4.xml · derivative · entry 1 Galletta Christopher · CIK 0001486099 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-12 F1 · derivative.exercise_date: This option was granted on April 13, 2021. The 25,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on April 12, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter, through April 12, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.